China SXT Pharmaceuticals, Inc. (SXTC)

China SXT Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is April - March.

Year Ending	TTM	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019
Revenue	0.03	0.03	0.34	0.88	0.33	0.21
Revenue Growth (YoY)	-	-90.09%	-61.68%	167.83%	55.75%	-83.89%
Cost of Revenue	-1.08	-1.55	-1.35	-1.94	-2.46	-2.4
Gross Profit	1.11	1.58	1.69	2.82	2.79	2.61
Selling, General & Admin	14.43	6.03	6.44	5.04	4.04	2.84
Operating Expenses	14.43	6.03	6.44	5.04	4.04	2.84
Operating Income	-13.32	-4.45	-4.75	-2.21	-1.26	-0.23
Interest Expense / Income	0.43	0.48	0.04	1.62	3.35	0.01
Other Expense / Income	0.38	1	0.62	-0.89	5.78	-2.03
Pretax Income	-14.14	-5.93	-5.41	-2.94	-10.39	1.79
Income Tax	0	0	0.33	-0.19	-0.1	0.25
Net Income	-14.14	-5.93	-5.74	-2.75	-10.29	1.54
Net Income Growth	-	-	-	-	-	29.61%
Shares Outstanding (Basic)	1	0	0	0	0	0
Shares Outstanding (Diluted)	1	0	0	0	0	0
Shares Change	1512.49%	541.90%	44.50%	132.79%	20.23%	2.84%
EPS (Basic)	-26.96	-22.23	-137.93	-95.47	-832.05	149.50
EPS (Diluted)	-26.96	-22.23	-137.93	-95.47	-832.05	149.50
EPS Growth	-	-	-	-	-	26.69%
Free Cash Flow	-0.16	-0.15	0.21	-1.41	0.53	-0.36
Free Cash Flow Per Share	-0.32	-0.57	4.95	-48.98	42.67	-34.97
Gross Margin	3703.22%	4696.56%	498.27%	318.99%	844.05%	1231.48%
Operating Margin	-44530.39%	-13249.91%	-1401.12%	-250.13%	-380.06%	-108.13%
Profit Margin	-47248.64%	-17651.98%	-1691.43%	-310.53%	-3113.48%	725.52%
Free Cash Flow Margin	-540.69%	-450.44%	60.69%	-159.28%	159.67%	-169.51%
Effective Tax Rate	-	-	-	-	-	14.08%
EBITDA	-13.36	-5.13	-5.05	-0.98	-6.71	1.98
EBITDA Margin	-44641.31%	-15272.60%	-1489.49%	-110.74%	-2030.37%	932.13%
Depreciation & Amortization	0.35	0.32	0.32	0.35	0.33	0.18
EBIT	-13.71	-5.46	-5.37	-1.33	-7.04	1.8
EBIT Margin	-45814.74%	-16233.89%	-1583.85%	-149.77%	-2130.80%	846.85%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).